Funding to accelerate development of AI-driven tumour profiling tool OneMap One Biosciences has secured €15 million in Series A financing to expand its AI-powered single-cell transcriptomic platform, ...

The move significantly expands and diversifies AbbVie’s revenue base AbbVie has wrapped up its $63 billion acquisition of Allergan plc following receipt of regulatory approval from all government ...

Deucrictibant shows rapid symptom relief and strong safety profile in RAPIDe-3 study Pharvaris has announced positive topline data from its RAPIDe-3 pivotal phase 3 study, confirming the potential of ...

A new treatment for asthma and COPD attacks could revolutionise patient care, scientists say. An injection given during attacks is more effective than the current steroid tablet treatment, reducing ...

SBT-77-7101 shows favourable safety and early signs of efficacy in patients with refractory RA Sonoma Biotherapeutics has announced positive interim results from its ongoing phase 1 Regulate-RA trial ...

New data from Janssen-Cilag International NV suggest that subcutaneous DARZALEX (daratumumab) quadruplet therapy could offer a longer progression free survival for patients with newly diagnosed ...

A British inquiry into the use of chemotherapy to treat seriously ill cancer patients has found the treatment caused or hastened death in 27% of cases. A British inquiry into the use of chemotherapy ...

In the UK, the progressive neurodegenerative condition affects around 153,000 people Herantis Pharma has been awarded €3.6m in funding from Parkinson’s UK’s Virtual Biotech programme and the Michael J ...

Global biopharma Eli Lilly will acquire SiteOne Therapeutics, a biotech dedicated to the development of non-opioid medicines to treat pain and other neuronal hyperexcitability disorders, to advance ...

JHU083 reduced tumour growth and triggered tumour cell death in mice Researchers from the Johns Hopkins Kimmel Cancer Center and Johns Hopkins Drug Discovery have revealed that a novel therapy can ...

New study to test Sema3A antibody in rare genetic kidney disease Evotec SE has announced that partner Bayer AG has initiated a phase 2 clinical study of BAY 3401016, a monoclonal antibody targeting ...

Therapy is a positive modulator and has demonstrated that it can improve learning and memory Therapy is a positive modulator and has demonstrated that it can improve learning and memory AlzeCure ...